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Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease that results in progressive loss
of motoneurons, motor weakness and death within 1^5 years after disease onset.Therapeutic options remain
limited despite a substantial number of approaches that have been tested clinically. In particular, various neuro-
trophic factorshave beeninvestigated.Failureinthese trialshasbeenlargely ascribedtoproblems of insufficient
dosingorinabilityto crosstheblood^brainbarrier (BBB).Wehaverecentlyuncoveredtheneurotrophicproperties
of the haematopoietic protein granulocyte-colony stimulating factor (G-CSF).The protein is clinically well toler-
atedandcrossestheintactBBB.ThisstudyexaminedthepotentialroleofG-CSFinmotoneurondiseases.Weinves-
tigated the expression of the G-CSF receptor in motoneurons and studied effects of G-CSF in a motoneuron cell
line andin the SOD1(G93A) transgenic mouse model.The neurotrophic growth factor was appliedboth bycontin-
uous subcutaneous deliveryand CNS-targetedtransgenicoverexpression.This study showsthatgiven atthe stage
of the diseasewhere muscle denervation is already evident,G-CSF leads to significant improvement in motor per-
formance, delaysthe onsetofseveremotorimpairment andprolongsoverallsurvivalof SOD1(G93A)tgmice.The
G-CSFreceptorisexpressedbymotoneuronsandG-CSFprotectsculturedmotoneuronalcellsfromapoptosis.In
ALS mice, G-CSF increased survival of motoneurons and decreased muscular denervation atrophy. We
conclude that G-CSF is a novel neurotrophic factor for motoneurons that is an attractive and feasible drug candi-
date for the treatment of ALS.
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Abbreviations: ALS=amyotrophic lateral sclerosis; BBB=blood^brain barrier; CHAT=choline acetyltransferase;
G-CSF=granulocyte-colony stimulating factor; SOD1=superoxide dismutase1
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Introduction
Amyotrophic lateral sclerosis (ALS) is an incurable fatal
motoneuron disease with a lifetime risk of 1:800. It is
characterized by progressive weakness, muscle wasting and
death ensuing 3–5 years after diagnosis (Mitchell and
Borasio, 2007). Currently, the only available treatment
option is riluzole that prolongs life by 2–3 months, with
questionable functional improvement (Miller et al., 2007).
The causes of sporadic ALS are unknown but several genes
have been identified that pose a genetic risk of developing
ALS (Dunckley et al., 2007). In contrast, a number of genes
have been identified that, when mutated, cause familial
ALS. The best studied of those are mutations in the gene
encoding superoxide dismutase 1 (SOD1), responsible for
about 2% of all ALS cases.
A number of drug candidates have been proposed but
failed in clinical trials. Several reasons have been put
forward for this failure, including inability to pass the
blood–brain barrier, intolerable side effects and insufficient
dosing. Since the exact disease-causing mechanism(s) is
unclear at present, a rational approach is to give general
trophic support to motoneurons, e.g. by growth factors.
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permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.We have recently uncovered the neuroprotective and
regenerative properties of the haematopoietic growth factor,
granulocyte-colony stimulating factor (G-CSF) (Schneider
et al., 2005; Schabitz et al., 2008). Receptors for this factor
are present in different brain regions with predominantly
neuronal localization (Schneider et al., 2005). G-CSF
improves outcome in various stroke models, both with
regard to infarct size (Schneider et al., 2005, 2006) and
long-term functional recovery (Gibson et al., 2005;
Schneider et al., 2006). Together with EPO and the newly
discovered neuronal effects of granulocyte-macrophage
colony stimulating factor (Kruger et al., 2007; Schabitz
et al., 2008), these proteins form a novel class of neuro-
trophic factors. G-CSF is a 19.6kDa protein that also passes
the intact blood–brain barrier, allowing for peripheral
delivery of this protein for the treatment of neurological
conditions (Schneider et al., 2005; Zhao et al., 2007).
A major practical advantage of these factors in the
treatment of diseases of the brain is their demonstrated
safety profile in the traditional clinical indications. G-CSF is
clinically used for chemotherapy-associated neutropaenia
and stem cell harvesting. In this study, we show that G-CSF
is a novel drug candidate for the treatment of ALS.
Materials and Methods
ALS model
We used mice transgenic for the SOD1(G93A) mutation (Gurney
et al., 1994) on a C57BL/6 background (B6.Cg-Tg(SOD1-
G93A)1Gur/J strain; Jackson Laboratory, Bar Harbour, ME,
USA), harbouring the high copy number of the mutant allele
human SOD1. The hemizygous line was maintained by mating
transgenic males with C57BL/6 wild-type females. Transgenic
females were used in all experiments. Experiments were performed
in a total of four sequential, age-matched cohorts with equally
distributed siblings to treatment and control groups.
T reatment protocol
G-CSF (filgrastim, AMGEN, Thousand Oaks; 30mg/kg/day) was
delivered continuously via an osmotic, subcutaneously implanted,
paravertebrally located minipump (Alzet Minipump, model 2004;
ALZET Osmotic Pumps, Cupertino, CA, USA). The solvent or
vehicle consisted of 250mM sorbitol, 0.004% Tween-80 and
10mM sodium acetate buffer (pH 4). Treatment was initiated in
all mice at 11 weeks (77 days) of age, for a total of 8 weeks. The
minipump was replaced once after 4 weeks.
Assessment of disease progression
Rotarod performance was assessed weekly using the accelerating
mode from 3 to 30 r.p.m. Cutoff time was 470s. Mean of three
testings was recorded. Grip strength measurements were done
weekly. Mean of three testings was recorded. Clinical onset of
disease was defined as the beginning of paralysis of one limb (hind
limb). Onset of disease by quantitative tests was defined as a drop
in performance to 580% of the initial value (rotarod and grip
strength measurements). Clinical end stage was defined as the
inability of the animal to right itself over a period of 30s. Animals
were sacrificed at that point. By rotarod and grip strength analysis,
clinical end stage was defined as a drop in performance to 520%
of the initial value.
Sciatic nerve axotomy
Wild-type mice were anaesthetized using isofluran/N2O anaesthe-
sia. The left hind leg was slightly stretched and fixated. After
dorsal skin incision, the sciatic nerve was carefully exposed and
completely cut through with microscissors, 5mm proximal to the
bifurcation of the tibial and common peroneal nerve. ALZET
minipumps were implanted as above. After 4 weeks, animals were
sacrificed and muscles subjected to histology.
Polymerase chain reaction analysis
of differentiated NSC34 cells
NSC34 cells were obtained from Dr Neil Cashman (University of
Toronto, Ontario, Canada). Cells were cultured in 15cm plates with
high-glucose Dulbecco modified Eagle medium+10% foetal calf
serum+1% penicillin/streptomycin+1% L-glutamine, then split
onto 10cm plates at a density of 3 10
6 cells/plate and differentiated
after a minimum of 3 days in vitro in high-glucose Dulbecco
modified Eagle medium/Ham’s F-12 (1:1) (Invitrogen)+1% foetal
calf serum+1% non-essential amino acids+1% penicillin/strepto-
mycin+1% L-glutamine. Cells were scraped off a 10cm plate in
solution D+(4M guanidine thiocyanate, 25mM sodium citrate,
0.5% sarkosyl, 0.1M mercaptoethanol) and RNA extracted by
acid phenol–chloroform extraction followed by RNeasy columns
(Qiagen, Hilden, Germany). Complementary DNA was synthesized
using superscript II reverse transcriptase (Invitrogen, Karlsruhe,
Germany) and standard buffers. Polymerase chain reaction (PCR)
was run for 32 cycles with an annealing temperature of 60 C and a
measuring temperature of 81 C. The following primer pairs were
used: murine G-CSF (G-CSF-790s: GGAGCTCTAAGCTTCTAG
ATC; G-CSF-1154as: TAGGGACTTCGTTCCTGTGAG; product
length 364bp) and murine GCSF-R (GCSFR-2582s: TGTGCCCCA
ACCTCCAAACCA; GCSFR-2817as: GCTAGGGGCCAGAGACAG
AGACAC; product length 235bp). Negative controls didnot contain
target DNA.
Quantitative reverse transcription^polymerase
chain reaction
RNA was isolated from spinal cords using the acidic phenol
extraction method followed by purification with the RNeasy Mini
Kit (Qiagen), according to the manufacturer’s recommendations.
Complementary DNA was synthesized from 1mg total RNA
using oligo-dT primers and superscript II reverse transcriptase
(Invitrogen), according to standard protocols. Quantitative reverse
transcription–polymerase chain reaction (RT–PCR) was performed
using the Lightcycler system (Roche) with SYBR-Green staining of
double-stranded DNA. Cycling conditions were as follows: 10min
at 95 C; 5s at 95 C, 10s at the respective annealing temperature,
30s at 72 C for 50 cycles and 10min at 95 C. The following
primer pairs were used (annealing and SYBR-Green measuring
temperature in parentheses): G-CSF [‘G-CSF-790s’: GGA GCT
CTA AGC TTC TAG ATC; ‘G-CSF-1154as’: TAG GGA CTT CGT
TCC TGT GAG (64 C, 81 C)], G-CSF receptor [‘G-CSFR-2582s’:
TGT GCC CCA ACC TCC AAA CCA; ‘G-CSFR-2817as’: GCT
AGG GGC CAG AGA CAG AGA CAC (64 C, 81 C)], NSE
[‘mm NSE-p’: GGC AAG GAT GCC ACT AAC GT; ‘mm NSE-m’:
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[‘rat PLP-518s’: TCA TTC TTT GGA GCG GGT GTG;
‘mm PLP-927as’: TAA GGA CGG CGA AGT TGT AAG TGG
(60 C, 85 C)], GFAP [‘mm GFAP-p’: CCC AGC TGG TTA GAA
TTG GA; ‘mm GFAP-m’: GGC TAG AGA GAC TTT GCC TC
(60 C, 82 C)], IBA1 [‘mm iba-1 172s’: TGT GGA AGT GAT GCC
TGG GA; ‘mm iba-1 419as’: GGG ATC ATC GAG GAA TTG CTT
(60 C, 85 C)], THY1 [‘murine thy-1 1167 sense’: ACA CAA GCG
CTC TGC CAT CAC TG; ‘murine thy-1 1477 antisense’: GAG
GGG CAA GGG AAA GAA GAA TAA (60 C, 84 C)], Bcl-Xl
[‘Mm Bcl-xL sense’: CAG TTT GGA TGC GCG GGA GGT AAT;
‘Mm Bcl-xL antisense’: AGT GCC CCG CCA AAG GAG AAA
AAG (64 C, 85 C)]. Specificity of product was ensured by melting
curve analysis and agarose gel electrophoresis. Relative regulation
levels were derived after normalization to cyclophilin [‘cyc5’: ACC
CCA CCG TGT TCT TCG AC; ‘acyc300’: CAT TTG CCA TGG
ACA AGA TG (60 C, 82 C)].
SOD1 levels
Analyses were performed on spinal cords of SOD1 transgenic mice
receiving G-CSF or vehicle at week 19. To determine SOD1 levels
on the mRNA level, quantitative PCR was performed using the
following primers: mouse SOD1 ‘Mm SOD1’: sense, GGG TTC
CAC GTC CAT CAG TAT GG; antisense, GGC TCC CAG CAT
TTC CAG TCT TTG; product length 297bp. Human SOD1 ‘Hum
SOD1’: sense, GTG GGG AAG CAT TAA AGG ACT GAC;
antisense, CAA TTA CAC CAC AAG CCA AAC GAC; product
length 355bp. Protein levels were determined by Western blot
using antibodies against human SOD (Calbiochem) or mouse
SOD1 (Chemicon). Actin (anti-mouse-actin; Chemicon) was used
as internal standard. Western blots were quantified using Image J.
Caspase activity assays
For Caspase 3/7 assays, we used the mouse neuroblastoma-
motoneuron fusion cell line NSC34. Cells were differentiated as
described earlier. Differentiated cells were seeded into 96-well
plates (2 10
4 cells/well) for 2 days. To elicit programmed cell
death cells were treated with 1mM staurosporine (Merck-
Calbiochem) for 5h with or without recombinant human
G-CSF (Filgrastim, AMGEN) at a concentration of 50ng/ml.
Incubation was continued for 5h and Caspase 3/7 activity was
determined by the CaspaseGlow assay (Promega) with a
luminescence plate reader (Mithras, Berthold technologies). Eight
independent data points were generated for each treatment.
Akt phosphorylation enzyme-linked
immunosorbent assay
To determine possible activation of Akt kinase in NSC34 cells by
G-CSF, we utilized the phosphoAkt-Elisa Kit (R&D Systems,
Wiesbaden, Germany). NSC34 cells were seeded with differentia-
tion medium into 24-well plates at a density of 8 10
5 cells/well
for 3 days. Vehicle or G-CSF was added to a concentration of
50ng/ml. Treated groups were lysed after 10 or 60min, the vehicle
control at 60min. The cell lysate was processed according
to manufacturer’s recommendations. Briefly, the whole lysate
was added to the test plate, incubated for 2h at room tempera-
ture and developed with a streptavidin/horseradish peroxidase
substrate. Optical densities were measured at 450 and 570nm
(Fluostar, BMG Laboratories, Germany) and pAkt levels were
derived from the difference in optical densities and a standard
curve and normalized to cell numbers. Absolute values were
measured as nanogram per 10
4 cells and converted to relative
levels. Four independent data points were obtained for each
group.
Immunohistochemistry
After deep anaesthesia, mice were transcardially perfused with
Hank’s balanced salt solution followed by 4% paraformaldehyde;
spinal cords were removed and embedded in paraffin. For G-CSF
receptor immunohistochemistry on human spinal cord (tissue
kindly provided by Dr J.P. Loeffler, Universite ´ Louis Pasteur,
Strasbourg, France), sections of paraffin-embedded tissues (10mm)
were deparaffinated and microwaved (citrate buffer at 600W for
15min). After overnight incubation of sections at 4 C with the
G-CSF receptor antiserum (SC-694; Santa Cruz Biotechnology,
Santa Cruz, CA, USA; 1:100), staining was visualized using the
ABC technique with 3,30-diaminobenzidine hydrochloride as
chromogen (DAKO). For double-immunofluorescence, sections
of paraffin-embedded tissues (10mm) were deparaffinated and
microwaved as described above. Thereafter, sections were
incubated at 4 C overnight, simultaneously with the GCSF
receptor antiserum (SC-694; Santa Cruz Biotechnology, Santa
Cruz, CA, USA; 1:100), the calcitonin gene-related peptide
antibody (1720-9007; Biogenesis Ltd, Poole, UK; 1:200), the
ChAT antibody (AB144P; Chemicon Europe Ltd, UK; 1:100) or
the GFAP antibody (MAB 360; Chemicon Europe Ltd, UK; 1:100).
After enhancing the G-CSF receptor staining by adding biotinylated
anti-rabbit secondary antibody (Dianova, Hamburg, Germany;
1:200), sections were incubated with streptavidin-coupled fluor-
ophore (Invitrogen, Karlsruhe, Germany; 1:200) or the appro-
priate fluorescence-coupled secondary antibody (Dianova,
Hamburg, Germany; 1:200). The nuclei were counterstained with
Hoechst 33342 (Molecular Probes, 1:10 000). Controls included
omission of primary antibodies, fluorescence swapping and single-
fluorescence stainings.
Stability of G-CSF released from subcutaneously
implanted minipumps
Osmotic minipump (Alzet Minipump, model 2004, ALZET
Osmotic Pumps, Cupertino, CA, USA) filled with 0.1mg/ml
G-CSF (Filgrastim, AMGEN, Thousand Oaks; 30mg/kg/day) in
10mM acetate buffer, pH 4, 250mM sorbitol and 0.004% Tween-
80 were implanted subcutaneously in a paravertebral position in
C57BL/6 mice. This results in a release of 30mg G-CSF/kg body
weight over 24h for a mouse of 20g weight. The absolute release
rate is 0.025mg G-CSF/h. Serum concentration of G-CSF was
determined at days 1, 7 and 28 by enzyme-linked immunosorbent
assay (ELISA) (QuantiGlo human G-CSF chemiluminescent ELISA
Kit, R&D Systems, Wiesbaden, Germany). The serum was
processed according to the manufacturer’s recommendations.
Briefly, the diluted serum was added to the test plate, incubated
for 2h at room temperature and developed with a luminol/
hydrogen phosphate substrate. Chemoluminescence was measured
(Luminometer, Berthold, Bad Wildbad, Germany) and G-CSF
levels were derived from the difference in the chemoluminescence
and standard curve. Five mice were treated for each time point.
Measurements were performed in duplicates.
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C57BL/6 mice received G-CSF (filgrastim, AMGEN, Thousand
Oaks; 30mg/kg/day) for 4 days via an osmotic, subcutaneously
implanted, paravertebrally located minipump (Alzet Minipump,
model 2004, ALZET Osmotic Pumps, Cupertino, CA, USA).
Control animals received only vehicle (250mM sorbitol, 0.004%
Tween-80 and 10mM sodium acetate buffer, pH 4). Spinal cords
were dissected after careful transcardial perfusion with Hank’s
balanced salt solution. Entire spinal cords were homogenized in
lysis buffer (Promega) and equal amounts of protein (200mg)
were analysed by an ELISA for human G-CSF (R&D Systems).
Counting of motoneurons
Coronal paraffin sections from the lumbar spinal cord were
stained for choline acetyltransferase (CHAT)-positivity using the
avidin–biotin complex (ABC) technique with 3,30-diaminobenzi-
dine hydrochloride as chromogen (DakoCytomation). All neurons
in the ventral horn that had a clearly identifiable nucleolus, were
4400mm
2 in size and were CHAT-positive were counted. Eleven
sections per mouse spinal cord that were 100mm apart over a
length of 1mm isolated from the lumbar spinal cord were
counted. A total of 14 mice was counted from the vehicle (5),
verum (5) and wildtype (4) group.
Counting of muscle fibre diameters
Paraffin sections (10mm) from indicated muscles (M. quadriceps,
M. tibialis) were cut transversally to the length axis of the muscle
and stained with haematoxylin and eosin. Countings were
performed using Mercator software (ExploraNova, La Rochelle,
France), a stereological toolbox.
Electromyography
Single fibre potentials were measured by inserting a concentric
electromyography-needle electrode with an outer diameter of
350mm (Schuler Medizintechnik GmbH, Freiburg, Germany) into
the right M. gastrocnemius of anaesthetized (Isoflurane/N2O)
mice. Data were recorded with a PowerLab 4/25 system
(ADInstruments GmbH, Spechbach, Germany) at a sample rate
of 10 000Hz. To provide low noise with highest electronic
amplification factors, a bioamplifier with headstage system
(DAM80, World Precision Instruments, Berlin, Germany) was
used (settings: 10 000, low filter of 300Hz and high filter of
3kHz). External electromagnetic influence was strongly reduced by
a customized Faraday cage (iron mesh with 1mm wire diameter
and open mesh size of 1cm 1cm) and an electrically grounded
steel base plate.
Generation of G-CSF overexpressing mice
We cloned the complementary DNA for murine G-CSF in a
bidirectional Tet-transactivator responsive vector (pBI, Clontech).
EYFP was inserted on the other side of the promoter for easy
visualization of expression. To generate the pBI-EYFP-G-CSF
(‘pBEG’) plasmid, G-CSF was amplified from a mouse brain
complementary DNA library and inserted into the pBI Tet Vector
(Clontech) with NheI and EcoRV, EYFP was inserted into
the multiple cloning site I of the vector. Transgenic mice
(‘BEG’) were generated and selected for copy number integration.
Copy numbers were estimated by quantitative PCR on genomic
DNA by comparing pBEG/cyclophilin ratios of wt and founder
mice. The following primer sets were used: pBI-ABG_3947s
(GCT GTT GAG ATC CAG TTC GA), pBI-ABG_4788as (AGT
CGA CCT AGT TCT AGA GG), cyc5 (ACC CCA CCG TGT
TCT TCG AC), acyc300 (CAT TTG CCA TGG ACA AGA TG).
Amplification conditions were 60 C annealing and 81 C measur-
ing temperature for the cyclophilin product, and 62 C annealing
and 91 C measuring temperature for the pBI-ABG product.
Mice of the line BEG6 were crossed with mice expressing the
Tet-transactivator (tta) under control of the Thy1-promoter
(Thy1-tta) and successful activation of the construct was verified
by EYFP imaging.
Statistics
Experiments were performed in a randomized and blinded
manner, including computer-generated probe randomizations
and probe labelling, blindness of all experimenters to treatment
identities until the end of the experiment and separation of data
analyses from experiment conduction. Animals were age- and
litter matched. Group or pairwise parametric or non-parametric
comparisons were done using NCSS software (NCSS, Kaysville,
UT, USA). Survival and onset data were analysed using log-rank
test. Area under the curve was determined using the trapezoidal
algorithm. P-value 50.05 was considered significant. All animal
experiments were approved by the appropriate authorities
(Regierungspra ¨sidium Karlsruhe, Germany).
Results
The G-CSF receptor is expressed on
motoneurons and G-CSF protects against
apoptotic cell death
The G-CSF receptor (G-CSFR) is predominantly neuronally
expressed in the brain (Schneider et al., 2005). When
studying G-CSF receptor expression in the mouse spinal
cord, we noted strong expression in the large motoneurons
in the ventral horn identified by either calcitonin gene-
related peptide or CHAT expression (Fig. 1A and B).
Neuronal expression was also confirmed by counterstaining
with the astroglial marker GFAP (Fig. 1C and D). G-CSF
receptor expression in motoneurons was also confirmed
in rat (data not shown) and human (Fig. 2A–C). This
motoneuronal expression pattern was also preserved in
an ALS patient (Fig. 2D–F) and the SOD1(G93A) mouse
model (SupplementaryFig. S1). These expression data
suggest that G-CSF may have protective potential in
motor neuron diseases such as ALS.
To address the function of G-CSF in motoneurons,
we used the well-established murine motoneuron fusion
cell line NSC34 (Cashman et al., 1992) that has key
characteristics of motoneurons and intact cell death
mechanisms that are of relevance to ALS pathophysiology
(Oosthuyse et al., 2001; Fukada et al., 2004; Kirby et al.,
2005). Differentiated NSC34 cells express both the G-CSF
receptor and G-CSF (Supplementary Fig. S2). Addition of
G-CSF to the medium leads to activation of Akt kinase,
3338 Brain (2008),131, 3335^3347 C. Pitzer et al.determined by its phosphorylation (Fig. 3A). G-CSF
strongly reduced caspase-3 activation elicited by the
broad-spectrum apoptosis inducer, staurosporin (Fig. 3B).
This protective activity of G-CSF in NSC34 cells is
supported by data showing protection against H2O2-
induced cell death (Tanaka et al., 2006).
Subcutaneous delivery of G-CSF improves
functional motor performance in the
SOD1(G93A)tg mouse model
The most valuable model for ALS are mice transgenic for
human mutations in the SOD1 gene, responsible for about
20% of the familial ALS cases (Bendotti and Carri, 2004;
Bruijn et al., 2004). For all further analyses we employed
the high copy number SOD1(G93A)-transgenic mouse
model (Gurney et al., 1994) on a pure C57BL/6 background
(Heiman-Patterson et al., 2005) as these mice exhibit a
highly stable phenotype and display no gender differences
in disease progression (Heiman-Patterson et al., 2005). We
detected G-CSF receptor and G-CSF upregulation in SOD1-
tg mice that were at a progressed stage of disease (week 19)
as an indication of possible relevance of the G-CSF system
in this mouse model (45-fold upregulation of the G-CSF
receptor; Fig. 3C).
Consequently, we sought to evaluate effects of systemic
G-CSF treatment in this ALS model. Our choice of a
treatment regimen was partially guided by our experience
in ischemic models where we find efficacy with a one-dose
treatment of 60mg/kg bodyweight (Schabitz et al., 2003;
Schneider et al., 2005, 2006) and in the MPTP model where
a daily dose of 40mg/kg bodyweight showed protective
effects (Meuer et al., 2006). G-CSF has a moderate plasma
half-life of about 4h in humans and rodents and a number
of neurotrophic factors have likely failed in ALS due to
short half-lives and low steady-state levels (Apfel, 2001).
Under the assumption of a neuroprotective effect on moto-
neurons in a continuously progressing disease course,
GCSFR CGRP merge
merge GCSFR CHAT
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D
Fig. 1 G-CSFR is expressed on motoneurons in the spinal cord of wt mice. (A^D), Immunohistochemistry shows expression of the
receptor on large motoneurons in the spinal cord. Double immunfluorescence of G-CSFR and CGRP (calcitonin gene-related peptide) or
CHAT (choline acetyltransferase) in the mouse spinal cord ventral horn.CGRP and CHATare used as marker for motoneurons. Double
immunfluorescence of G-CSFR and GFAP revealed the absence of G-CSFR in astrocytes. (A^C: 20 original magnification; all size bars
50mm; D: 40 original magnification, size bar 25mm).
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subcutaneously implanted osmotic minipumps for a total
of 8 weeks, starting with week 11. At 11 weeks, SOD1-tg
mice did not display overt signs of the disease but already
showed muscle fibrillations as early manifestation of the
disease (Supplementary Fig. S4). G-CSF was stably secreted
under these conditions for the 4 week period until pumps
were exchanged (Supplementary Fig. S3). Peripherally
applied G-CSF passes the intact blood–brain barrier
(Schneider et al., 2005; Zhao et al., 2007). Human G-CSF
released by subcutaneous pumps for 4 days in C57BL/6 mice
also could be detected at a concentration of 4.2pg G-CSF/mg
spinal cord protein (Supplementary Fig. S5). G-CSF treat-
ment did not alter expression of the endogenous or the
transgenic SOD1 mRNA or protein when examined at the
end of treatment (week 19; Supplementary Fig. S6).
G-CSF induces expression of anti-apoptotic Bcl-protein
in neurons (Schneider et al., 2005). We asked whether
we could detect induction of Bcl-Xl in the spinal cord of
SOD1-transgenic mice under treatment with G-CSF.
Indeed, G-CSF treatment led to induction of Bcl-Xl
mRNA compared with SOD1-transgenic treated with
vehicle (Fig. 3D), as an indication of anti-apoptotic activity
of G-CSF in the spinal cord of SOD1-transgenic mice.
Vehicle-treated SOD1-tg mice progressively declined in
their rotarod performance with a strictly linear slope.
G-CSF treatment led to a flattening of disease progression
with clear separation of the curves after 2–3 weeks of
treatment (Fig. 4A). This difference was significant both by
analysis of means per timepoint and by analysis of
individual areas under the curve. A similar difference was
observed for grip strength (measured in mN; Fig. 4B). The
difference in the mean areas under the curve is around
40% by both analyses. When looking at the time needed to
reach a 50% decline in rotarod performance from week 11,
there was a clear delay by 43 weeks in the G-CSF-treated
group until the half-maximal decline in performance was
reached (Fig. 4C).
G-CSF treatment counteracts muscle
atrophy in mutant mice
The major output pathway of ALS, defining its name, is the
inability of dying motoneurons, despite enlargement of
motor units, to give trophic support to dependent
myofibers. This denervation atrophy is typically more
patchy in contrast to peripheral nerve lesions due to the
stochastic nature of neuronal cell death. We asked whether
we could detect any correlate to the strongly improved
motor performance in hind limb skeletal muscle histology.
When measuring intrafascial diameters of the M. rectus
femoris of the quadriceps group at 15 weeks of age (after 4
weeks of treatment), we detected strong muscular atrophy
in the vehicle-treated SOD1-tg mice in comparison to wt
littermates. In contrast, the G-CSF-treated group had
significantly larger muscle diameters (55% increase in
diameter, Fig. 4D). In individual muscle fibres, we noted
a significant decrease in muscle fibre cross-sectional area in
the SOD1-tg animals, which was improved by G-CSF
treatment (Fig. 4E). Thus, the increase in functional motor
outcome is reflected in muscle morphology.
Occurrence of spontaneous discharges of skeletal muscle
fibres (‘fibrillations’) is one characteristic hallmark of
denervation and can be studied by needle electromyography.
At week 14, when rotarod performance separates in the two
treatment groups, the occurrence of fibrillations is signifi-
cantly decreased under G-CSF treatment (Fig. 4F and G).
Motor effects of G-CSF are caused
by increased survival of motoneurons
Because of the strong effects on muscle phenotype and
myotrophic properties of another motoneuron growth
factor, IGF-1 (Coleman et al., 1995; Shavlakadze et al.,
2005), we explored the possibility of a direct trophic effect
of G-CSF on skeletal muscle fibres. We studied chronic
denervation caused by unilateral sciatic nerve dissection.
Analysis of cross-sectional areas of the M. tibialis anterior
4 weeks after denervation indicated the expected decrease in
muscle diameter on the lesion side but G-CSF did not
increase the median diameter on the lesioned or the
unlesioned side (Supplementary Fig. S7). Therefore, the
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Fig. 2 TheG-CSFreceptorisexpressedonmotoneuronsin
humans. (A^C) Immunohistochemical stainings from theventral
hornof thespinalcordofacontrolpatient.(D^F) Stainings from an
ALSpatient(originalmagnifications from 10^40 areindicated).
3340 Brain (2008),131, 3335^3347 C. Pitzer et al.effect seen in the SOD1(G93A) model is most probably
caused by direct actions of G-CSF on motoneurons.
We therefore determined numbers and size distribution
of a-motoneurons in the lumbar spinal cord of the SOD-1
tg mice at 15 weeks of age that were defined as (i) being
situated in the ventral horn; (ii) having a clearly identifiable
nucleolus; (iii) having a minimum cross-sectional area
of 400mm
2 and (iv) staining positive for CHAT. This
combination of criteria was chosen to guarantee identifica-
tion of alpha motoneurons with high specificity (Weber
et al., 1997), which are critical for disease progression [e.g.
in contrast to  motoneurons, see Mohajeri et al., (1998)].
We also noted motoneurons with strong or weak CHAT
expression. As expected, motoneuron numbers were
significantly decreased in the SOD1(G93A) mutant mice
as compared with wt mice. This loss was ameliorated
by G-CSF treatment (Fig. 5A and B). This beneficial effect
was relatively stronger in the population of neurons
displaying strong CHAT reactivity, presumably those with
higher activity or larger motor fields. Regarding size
distribution, we noted that the SOD1(G93A) transgene, in
addition to a loss in motoneuron numbers, led to a
remarkable downward shift in the remaining motoneuron
size, likely due to a more selective demise of larger
motoneurons or shrinkage of already damaged motoneur-
ons (Fig. 5B and C).
We also surveyed possible effects of G-CSF on glial cell
types in the spinal cord by quantitative PCR. We observed
an expected strong increase in mRNA for microglial (IBA1)
and astroglial (GFAP) markers in the ALS model, which
was not significantly altered by G-CSF treatment (Fig. 5D).
Immunohistochemistry revealed predominant localization
of these cells in the ventral horn of the spinal cord (data
not shown). The pan-neuronal marker NSE was signifi-
cantly downregulated in the SOD1 model and there was a
trend towards higher NSE signals with G-CSF treatment.
A significant improvement by G-CSF treatment was noted
on the decrease of the oligodendroglial marker PLP in
SOD1-tg mice, possibly relating to expression of the G-CSF
receptor on oligodendrocytes (Schneider et al., 2005).
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Fig. 3 G-CSF diminishes caspase-activation in a motoneuron cell line, is upregulated together with its receptor in SOD1(G93A) transgenic
mice.Treatment with G-CSF induces Bcl-Xl expression in the spinal cord of SOD1mice. (A) G-CSF activates the PI3K-Akt pathway, as
demonstrated by an ELISA for phosphorylated Akt (n=4 per treatment, P50.05). (B) Staurosporin-elicited caspase3 activation is dimin-
ished by concomitant G-CSF addition (n=4 per treatment, P50.05). (C) G-CSF receptor (G-CSFR) and G-CSF are upregulated in SOD1-tg
mice.Quantitative PCR on wt and SOD1-tg mice at19 weeks of age (n=6^7 ;
 P50.05). (D) Bcl-Xl is upregulated by G-CSF treatment in
SOD1-tg mice at19 weeks of age (n=6^7;
 P50.05).
G-CSF improves outcome in ALS model Brain (2008),131, 3335^3347 3341In conclusion, G-CSF improves motoneuron survival
and the functional integrity of these neurons, indicated
by reduced denervation atrophy, reduced fibrillations and
relative preservation of motoneuron size distribution and of
choline-acetyltransferase expression.
G-CSF treatment delays onset and prolongs
survival in the SOD1(G93A)tg mouse
We compared timed parameters from the vehicle- and
G-CSF-treated groups (Fig. 6). Clinically relevant onset
of disease as defined by detectable signs of motor
deterioration in at least one limb was clearly delayed in
the G-CSF-treated group from a mean of 17 weeks to a
mean of 18.8 weeks (Fig. 6A). Likewise, when examining
the time until rotarod performance dropped below 80%
of the initial value at week 11 as a more quantifiable
parameter of initial significant motor deterioration,
we noted an increase by G-CSF treatment from a mean
of 15.2–19.2 weeks (Fig. 6B). This was also paralleled
by analysis of grip strength data (not shown). Clinical end
stage of disease, defined as inability of the mouse to right
itself within 30s, was also significantly delayed by G-CSF
treatment from 21.7 to 23.2 weeks (Fig. 6C). This was again
paralleled by looking at time of rotarod decrease below 80%
of the initial value (Fig. 6D) and by grip strength analysis.
Table 1 summarizes the timed data obtained.
Thus, G-CSF treatment delays onset and prolongs
survival in the SOD1 mouse model for ALS.
CNS-targeted overexpression of G-CSF
is sufficient to improve outcome
Finally, we chose an alternative approach to increase G-CSF
levels in the CNS. We generated transgenic mice harbouring
a bidirectional tta-reponsive construct with expression
0
50
100
150
200
250
300
350
400
450
11 13 15 17 19 21 23 25
age [weeks] age [weeks] age [weeks]
G-CSF
vehicle
0
100
200
300
400
500
600
700
11 13 15 17 19 21 23 25
0
0.2
0.4
0.6
0.8
1
10 15 20 25 30
G-CSF
vehicle
0
20
40
60
G-CSF
vehicle
*
ABC
D E F
G
0.5 -
0.5 -
1.0 -
1.0 -
0.5 -
0.5 -
1.0 -
1.0 -
0.5 -
0.5 -
1.0 -
1.0 -
mV
mV
mV
1.0 0
wt
SOD1tg; veh
SOD1tg; G-CSF
1 sec 0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0 wt
SOD1/veh
SOD1/G-CSF
*
m
u
s
c
l
e
 
d
i
a
m
e
t
e
r
 
[
m
m
2
]
0
100
200
300
400
*
m
y
o
f
i
b
e
r
 
a
r
e
a
 
[
m
m
2
]
f
i
b
r
i
l
l
a
t
i
o
n
s
 
[
m
a
x
.
 
H
z
]
R
o
t
a
r
o
d
 
[
s
]
G
r
i
p
 
s
t
r
e
n
g
t
h
 
[
m
N
]
T
i
m
e
 
t
o
 
5
0
%
 
d
r
o
p
 
i
n
 
R
o
t
a
r
o
d
E
M
G
 
[
m
V
]
Fig. 4 G-CSF improves motor function in SOD1-tg mice. SOD1transgenic mice were treated with subcutaneous G-CSF (30mg/kg/day) or
vehicle (vehicle, n=1 7 ;G-CS F ,n=18) starting at week11of age, where signs of muscle denervation are already obvious on EMG.The drugs
were continuously administered for 8 weeks with an osmotic minipump (Alzet 2004) that was implanted in a paravertebral position at11
weeks of age and exchanged at week15. (A) Rotarod performance.Graph depicts means   SEM over14 weeks. Inset: AUC, bar graph
depicts area under the curve analysis of the individual performance curves. (B) Grip strength.Graph depicts means   SEM over14 weeks
(mN). Inset: AUC, bar graph depicts area under the curve analysis of the individual performance curves.There is considerable improve-
mentin both motor parameters in the treated group ( 40% by AUC analysis; P50.05). (C) Kaplan^Meier analysis of the time passeduntil
rotarod performance dropped below 50% of the initial value. Inset: AUC analysis.There is a significant difference between vehicle and
G-CSF treatment in all parameters shown (log-rank test; P50.05). (D^G) G-CSF diminishes denervation atrophy in hind limb muscles of
SOD1-tg mice. Shown are (D) the diameter of the M. rectus femoris of the M. quadriceps group in wt, vehicle-treated and G-CSF-treated
SOD1-tg mice.There is a significant increase in the muscle diameter by G-CSF treatment. (E) Analysis of individual fibre diameters in the
quadriceps group.There is a significantincreasein fibre diameter by G-CSF treatmentcompared with thevehicle-treatedgroup. Shown is a
box-blot with median (white) and the 25% and 75% quartiles as box. (F and G) Quantification of single fiber potentials by electromyogra-
phy of the M. gastrocnemius in wt, vehicle- and G-CSF-treated SOD1-tg mice at week14.There is a significant decrease in fibrillations by
G-CSF treatment. (F) Maximal frequency of fibrillation. (G) Exemplary traces from the wt, vehicle- and G-CSF-treated SOD1-tg mice at
week 14 (
 P50.05).
3342 Brain (2008),131, 3335^3347 C. Pitzer et al.cassettes for murine G-CSF and the fluorescent marker
EYFP (‘pBEG’). These mice were intercrossed with
a transgenic tta driver line under control of the Thy1
promoter. Mice harbouring both the pBEG construct and
the Thy1-tta driver construct showed strong coexpression
of the marker EYFP in cortex layers II and V (Fig. 7A) and
strongly elevated levels of G-CSF protein in the brain and
spinal cord (Fig. 7B and C). In comparison, littermate
controls without the driver construct, but transgenic for
the pBEG construct, did not display EYFP expression
or elevated G-CSF levels in the CNS (Fig. 7A–C).
Heterozygous transgenic mice for pBEG and Thy1-tta
were subsequently crossed with SOD1(G93A) transgenic
mice and littermates analysed that harboured alleles for
both the SOD1(G93A) transgene and the pBEG transgene,
with or without the Thy1-tta allele. Presence of the SOD1
transgene did not alter activity of the Thy1-promoter, as
evidenced by quantitative PCR analyses of the endogenous
Thy1-mRNA (Supplementary Fig. S8A). Mice harbouring
the Thy1-tta-driver, the BEG transgene and the SOD1
transgene also demonstrated elevated levels of G-CSF in the
spinal cord (Supplementary Fig. S8B). Performance in the
rotarod and grip strength tests was significantly improved
in mice with the Thy1-tta allele in comparison to
littermates without the driver transgene (not shown).
When comparing survival, these mice had an increased
life expectancy by 10% (Fig. 7D), corroborating our results
from the systemic delivery of G-CSF.
Discussion
Therapeutic approaches in ALS
Despite the large international effort invested into ALS
research and the undoubtedly great progress that has been
made in the field, the basic disease-causing mechanism
remains unknown. The genes responsible for several familial
ALS forms have been identified and provide novel hints to
cellular events that may are involved in ALS pathophysiol-
ogy. The best-studied mutation and model are SOD1
mutations. However, intense research into the mechanism
responsible for the ALS phenotpye of SOD1 mutations
has generated a number of novel unexpected questions,
most notably on the motoneuron-intrinsic versus a tissue-
environmental effect of the mutated SODs (Beers et al.,
2006; Boillee et al., 2006; Miller et al., 2006; Nagai et al.,
2007).
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Fig. 5 G-CSF improves motoneuron survival in SOD1-tg mice.
(A) Quantification of surviving motoneurons in wt, vehicle-treated
and G-CSF-treated SOD-1tg mice at15 weeks of age.We counted
11sections per mouse spinal cord,100mma p a r t ,o v e ral e n g t ho f
1mm isolated from the lumbar spinal cord. A total of14 mice were
counted from the vehicle (5), verum (5) and wt (4) groups.There is
an increase in motoneurons by G-CSF treatment compared with
vehicle, particularly in strongly CHAT-positive and larger moto-
neurons. (B) Examples of the histological evaluation of CHAT-
positive cells in the ventral horn of the lumbar spinal cord of15
weeks wt and SOD-1tg mice treated with either vehicle or G-CSF.
Left,  10 original magnification; right:  40 original magnification;
size bar 100mm. (C) Morphometric evaluation of the size distribu-
tion of surviving motoneurons at15 weeks of age.There is an
upward shift in median size distribution by G-CSF treatment
(ANOVA on ranks; P50.05). (D) Evaluation of marker expression
for differentneural cell typesby quantitative PCR at week19.There
is no difference in GFAP (astrocytes) or IBA1 (microglia) between
vehicle and G-CSF treatment; however, a relative prevention of
PLP (oligodendrocyte) decrease in the SOD-tg animals.
G-CSF improves outcome in ALS model Brain (2008),131, 3335^3347 3343Disease-causing mechanisms that have been proposed
include glutamate toxicity, mitochondrial dysfunctions and
impaired energy metabolism, oxidative stress and reactive
oxygen species, protein aggregation pathology, impaired
axonal transport, inflammatory and autoimmune mecha-
nisms and others (McGeer and McGeer, 2005; Carri et al.,
2006; Vincent et al., 2008). These hypotheses have led to a
large number of trials that have not led to the introduction
of novel drugs for ALS patients with the exception of
riluzole, a glutamate modifier with modest efficacy. One
possible reason for the clinical failure of a large number of
drug candidates may be the complexity of the different cell
types and mechanisms involved and the use of drug
cocktails and combination therapies has been suggested as a
remedy (Carri et al., 2006). However, clinical development
of combination therapies is problematic.
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Fig. 6 Timed data for disease onset and endpoint. Kaplan^Meier graphs showing time to disease onset (A and B)o rt i m et oe n d - s t a g e
disease (C and D). (A) Clinical onset of disease defined by detectable signs of motor deterioration in at least one limb. (B)T i m et od r o p
below 80% of rotarod performance as an objective indicator of initial significant motor deterioration defined as onset. (C)C l i n i c a le n d
stage of disease defined as inability of the mouse to right itself within 30s. (D) Time to drop of rotarod performance below 20% as an
objective indicator of a significant terminal motor deterioration defined as disease end stage. (log-rank test; P50.05).
Table 1 Summary of timed data (weeks) regarding onset,
mid-point, and endstage of the disease in the
SOD1(G93A)-tg mice treated s.c. with G-CSF
Vehicle G-CSF Difference (%)
Time to clinical onset
Clinical 17.0 18.8 10.8
Rotarod 15.4 19.2 25.2
Grip Strength 15.0 18.1 20.4
Time to 50% impairment
Rotarod 18.4 21.6 17.8
Grip strength 17.4 20.1 15.2
Time to endstage
Clinical 21.7 23.2 7 .0
Rotarod 20.8 22.8 10.0
Grip strength 19.5 21.7 11.2
All differences are significant (logrank; p50.05).
3344 Brain (2008),131, 3335^3347 C. Pitzer et al.In the absence of an identified singular decisive
pathogenic process, providing generic trophic support
to motoneurons by growth factors remains a highly
rational approach. Currently, two of the most promising
candidates for treatment are the proteins IGF1 (Kaspar
et al., 2003) and VEGF (Azzouz et al., 2004; Storkebaum
et al., 2005). Indeed, one trial with recombinant IGF-1
had a positive outcome (Lai et al., 1997). Here we have
shown that the haematopoietic growth factor G-CSF
is effective in improving functional parameters and
prolonging survival in the SOD1(G93A) mouse model of
familial ALS.
Mechanism of action of G-CSF
SOD1 transgenic animals treated with G-CSF demonstrate
beneficial effects along the motor pathway: There are more
surviving motoneurons in the spinal cord that also appear
functionally more intact with larger diameters, electromyo-
graphic signs of denervation are reduced, muscle mass
is increased and animals show increased strength and
endurance and finally, increased survival. The effect of
G-CSF is most likely caused by direct protection of
motoneurons, as motoneurons in the spinal cord strongly
express the receptor for G-CSF, G-CSF is directly protective
in a motoneuronal cell line in culture and transgenic
overexpression of G-CSF in the CNS improves outcome.
At present we have no indication that glial cells might be
involved in mediating G-CSF’s action: astrocytes and most
microglia do not express the receptor and the numbers of
these cell types in the SOD1 model are not strongly altered
by treatment. It might be possible that immunomodulatory
activities of G-CSF also play a role.
We have observed higher PLP mRNA levels in the
G-CSF-treated SOD1 transgenic mice. This effect could be
indirect or direct. Either there is indeed separate enhance-
ment/rescue of oligodendrocyte function in the SOD1
model or, more likely, the higher PLP expression simply
reflects the presence of more surviving motoneurons and
thus myelinated axons.
Upregulation of G-CSF in the SOD1-tg model
We see induction of G-CSF and G-CSF receptor in spinal
cords of SOD1(G93A) transgenic mice. Upregulation of
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Fig. 7 Survival in SOD1(G93A) transgenic mice crossed with
transgenic mice expressing G-CSF in the CNS. (A) Double trans-
genic mice harbouring transgenes for the bidirectional construct
BEG (pBI; EYFP; G-CSF) under control of the tta-responsive
promotor and a thy1-tta driver express the marker EYFP in
the cortex predominantly in layers II and V. Shown is a coronal
frontotemporal section of the cortex. (B and C)L e v e l so fG - C S F
protein determined by ELISA in the brains and spinal cords of
the double transgenic mice.There is a strong elevation of G-CSF
concentration in the CNS of the transgenic mice. (D)S u r v i v a lp l o t
of SOD1(G93A)tg mice crossed with the BEG6line.The survival
analysis includes 24 Thy1-/BEG+/SOD1+,10 Thy1+/BEG+/SOD1+
and15 Thy1-/BEG-/SOD1+ mice.Blue lines show the survival in the
littermates lacking theThy1-tta driver that do not overexpress
G-CSF in the CNS; green lines, mice that express G-CSF in the
CNS. Survival is prolonged by 16.1 days (=10%; Mantel^Haenszel
hazard ratio: 5.92; P50.0001) in the G-CSF overexpressers
compared with theThy1 /BEG+/SOD1+ littermates, and by11.5
days (=7%; Mantel^Haenszel hazard ratio: 3.99; P50.005) when
compared withThy1 /BEG /SOD1+ littermates.
G-CSF improves outcome in ALS model Brain (2008),131, 3335^3347 3345G-CSF was also reported by Tanaka et al. (2006) in the CSF
of ALS patients using an ELISA approach. However, while
upregulation of G-CSF receptor was very prominent
in the ALS mouse model, Tanaka et al. (2006) report
downregulation of the receptor in the spinal cord of ALS
patients. These data were generated using measurements of
optical density of immunoreactivity from light microscopic
precipitation stains. This is a methodologically questionable
approach and likely not possible without using double-
fluorescent staining against an unaltered protein as standard
(Schneider et al., 2004). This methodological problem is
underlined by the fact that Tanaka et al. (2006) could not
confirm alterations of G-CSF levels by this approach. We
consistently see upregulation of the G-CSF receptor as a
reaction to different disease stimuli in the nervous system
and believe that this represents an endogenous protective
response of neurons (Schneider et al., 2005). We therefore
believe that the question of regulation of the G-CSF
receptor in ALS patients and possible correlation to the
mouse model is open at present.
Predictiveness of the SOD1-tg model
Recently the predictive value of the SOD1-tg model has
been questioned mostly because a human trial with the
positively tested drug minocycline demonstrated significant
worsening of disease progression in the active arm (Gordon
et al., 2007). However, the SOD1-tg model remains the only
model that reproduces the main features of the human
disease. A possible explanation of the discrepancy between
successfully tested drugs in the model and failures in the
clinical trials is inadequate conduction of preclinical studies
(Scott et al., 2008). Our study relied on a fully blinded
(both for treatment allocation as well as outcome measures)
and randomized design using littermate and age matching.
The effects have also been confirmed by a different delivery
approach, transgenic overexpression. We are therefore
confident that our results represent true effects of G-CSF.
Of note, we have also started treatment at a time when
SOD1 mice already display clear electromyographic dener-
vation signs.
Effect size
We have observed a total benefit in survival by 7% with
systemic delivery of G-CSF (or about 10% by a transgenic
approach) and an overall increase in strength and
endurance by about 40% during the observation period.
It is possible that prolonging treatment beyond the 8 week
period could have further increased the survival benefit.
The observed effect on survival might appear moderate; it is
however very difficult to compare this with other studies in
this model due to substantial differences in experimental
conditions between the animal studies performed to date
(Scott et al., 2008). In general, very large effects on survival
have only been obtained by siRNA targeting of the disease-
causing protein itself or by viral delivery of proteins.
In contrast, the effects observed on motor performance are
remarkably strong and it is tempting to speculate that this
might translate to longer periods of independence for
human patients.
Clinical application of G-CSF
G-CSF may have considerable practical advantages over
other discussed growth factors for the treatment of ALS: It
has a safe clinical track record in other indications (Hubel
and Engert, 2003), is generally well tolerated, passes the
intact blood–brain barrier (Schneider et al., 2005; Zhao
et al., 2007) and has already entered clinical development
in another neurological disorder, stroke (Schabitz and
Schneider, 2007). In addition, the pharmacology of G-CSF
is extremely well understood. Translation to clinical
development of G-CSF in ALS and possibly other
motoneuron disorders appears very feasible.
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